Cipla's North American business achieved a record $250 million revenue in Q1 FY25, a 13% year-on-year growth. The company's branded prescription business in India grew 10%, while overall India growth was offset by trade generics softness. Cipla's South Africa revenue grew 19% YoY in local currency terms. Net profit rose 17.4% to Rs 1,178 crore.
